Renalytix Valuation
Is RENX undervalued compared to its fair value, analyst forecasts and its price relative to the market?
Valuation Score
1/6Valuation Score 1/6
Below Fair Value
Significantly Below Fair Value
Price-To-Sales vs Peers
Price-To-Sales vs Industry
Price-To-Sales vs Fair Ratio
Analyst Forecast
Share Price vs Fair Value
What is the Fair Price of RENX when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.
Below Fair Value: Insufficient data to calculate RENX's fair value for valuation analysis.
Significantly Below Fair Value: Insufficient data to calculate RENX's fair value for valuation analysis.
Key Valuation Metric
Which metric is best to use when looking at relative valuation for RENX?
Key metric: As RENX is unprofitable we use its Price-To-Sales Ratio for relative valuation analysis.
| What is RENX's PS Ratio? | |
|---|---|
| PS Ratio | 13.7x |
| Sales | US$2.35m |
| Market Cap | US$32.16m |
| Key Statistics | |
|---|---|
| Enterprise Value/Revenue | 16.6x |
| Enterprise Value/EBITDA | -1.6x |
| PEG Ratio | n/a |
Price to Sales Ratio vs Peers
How does RENX's PS Ratio compare to its peers?
| Company | Forward PS | Estimated Growth | Market Cap |
|---|---|---|---|
| Peer Average | 1.7x | ||
IUG Intelligent Ultrasound Group | 4x | n/a | UK£39.3m |
COG Cambridge Cognition Holdings | 0.9x | 11.0% | UK£11.5m |
OPT Optima Health | 1.3x | 1.7% | UK£140.3m |
INHC Induction Healthcare Group | 0.7x | 13.0% | UK£8.4m |
RENX Renalytix | 13.7x | 126.2% | UK£25.7m |
Price-To-Sales vs Peers: RENX is expensive based on its Price-To-Sales Ratio (13.7x) compared to the peer average (1.7x).
Price to Sales Ratio vs Industry
How does RENX's PS Ratio compare vs other companies in the European Healthcare Services Industry?
| 5 Companies | Price / Sales | Estimated Growth | Market Cap |
|---|---|---|---|
| 5 Companies | Estimated Growth | Market Cap | |
|---|---|---|---|
Price-To-Sales vs Industry: RENX is expensive based on its Price-To-Sales Ratio (13.7x) compared to the European Healthcare Services industry average (2.2x).
Price to Sales Ratio vs Fair Ratio
What is RENX's PS Ratio compared to its Fair PS Ratio? This is the expected PS Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.
| Fair Ratio | |
|---|---|
| Current PS Ratio | 13.7x |
| Fair PS Ratio | 38.3x |
Price-To-Sales vs Fair Ratio: RENX is good value based on its Price-To-Sales Ratio (13.7x) compared to the estimated Fair Price-To-Sales Ratio (38.3x).
Analyst Price Targets
What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?
Analyst Forecast: Insufficient data to show price forecast.
Discover undervalued companies
Centene
US$30.5b
Operates as a healthcare enterprise that provides programs and services to under-insured and uninsured families, commercial organizations, and military families in the United States.
0HVB
US$60.47
7D
5.2%
1Y
-18.4%
Elevance Health
US$93.4b
Operates as a health benefits company in the United States.
0HG8
US$401.70
7D
-0.06%
1Y
-16.0%
Enovis
US$2.6b
Operates as a medical technology company focus on developing clinically differentiated solutions worldwide.
0I1B
US$46.90
7D
2.6%
1Y
-8.3%